Galmed Pharmaceuticals Ltd Shares Close the Week 21.3% Lower - Weekly Wrap
The company saw its shares close the week 21.3% lower than last week, with trading volume higher than its 30 day average.
Jan 12, 2022 by Kwhen Finance Editors
Galmed Pharmaceuticals Ltd (GLMD) shares closed this week 21.3% lower than it did at the end of last week. The stock is currently down 10.4% year-to-date, down 52.3% over the past 12 months, and down 60.7% over the past five years. This week, the Dow Jones Industrial Average fell 1.3%, and the S&P 500 fell 2.6%.
Trading Activity
- Shares traded as high as $2.10 and as low as $1.54 this week.
- Shares closed 73.1% below its 52-week high and 9.1% above its 52-week low.
- Trading volume this week was 432.0% higher than the 10-day average and 877.5% higher than the 30-day average.
- Beta, a measure of the stock’s volatility relative to the overall market stands at 0.7.
Technical Indicators
- The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
- MACD, a trend-following momentum indicator, indicates a downward trend.
- The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance
- The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis
- The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis
- The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis
| Name | DoD %Δ | YTD %Δ | 1 Yr % | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|
| Galmed Pharmaceuticals Ltd | 3.1 | -10.4 | -52.3 | -73.4 | 7.8 |
| Dow Jones Industrial Average | 0.5 | -0.7 | 18.0 | -2.4 | 22.8 |
| S&P 500 Index | 0.9 | -2.0 | 23.7 | -3.1 | 28.0 |
| Health Care | 0.8 | -4.3 | 14.2 | -4.7 | 22.4 |
Peer Group Comparative Performance
- The company's stock price performance year-to-date lags the peer average by -587.2%
- The company's stock price performance over the past 12 months lags the peer average by 29.7%
| Name | MKT CAP (USD) | P/E | YTD %Δ | 1 Yr %Δ | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|---|
| Galmed Pharmaceuticals Ltd | GLMD | 0 | -10.4 | -52.3 | -73.4 | 7.8 |
| Peer Avg | N/A | 11.9 | 2.1 | -40.4 | -58.3 | 35.6 |
| Catalent Inc. | CTLT | 37.2 | -7.6 | 5.2 | -16.9 | 21.2 |
| Endo International plc | ENDP | 12.9 | 0 | -46.7 | -65.3 | 94.8 |
| Aerie Pharmaceuticals Inc | AERI | -2.3 | 17.2 | -41.0 | -61.9 | 21.6 |
| Evoke Pharma Inc | EVOK | 0 | -1.1 | -78.8 | -89.1 | 4.9 |
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.
Was this content valuable for you?
Tags: